8-K: Clorox Announces Q4 and Fiscal Year 2024 Results, Divests Vitamins Business

Clorox reported its fourth quarter and fiscal year 2024 results, including a 6% net sales decrease for the quarter, and announced the sale of its Better Health Vitamins, Minerals and Supplements business.

Summary

• Clorox's net sales decreased by 6% in the fourth quarter of fiscal year 2024 to $1.9 billion, compared to a 12% increase in the same quarter last year, with organic sales down 3%.
• The decrease in net sales was primarily due to the divestiture of the Argentina business, unfavorable price mix, and lower volume.
• Gross margin increased by 380 basis points to 46.5%, driven by lower manufacturing and logistics costs, cost savings initiatives, and favorable commodity costs.
• Diluted earnings per share (EPS) increased by 22% to $1.73, which includes insurance recoveries related to the cyberattack, partially offset by investments in digital capabilities and the streamlined operating model.
• Adjusted EPS increased by 9% to $1.82, due to higher gross margin and lower selling and administrative expenses, partially offset by lower net sales and higher advertising investments.
• For the full fiscal year 2024, net sales decreased by 4%, but organic sales were flat, with a 360 basis point increase in gross margin to 43.0%.
• Diluted EPS for the full year increased by 88% to $2.25, and adjusted EPS increased by 21% to $6.17.
• The company has entered into a definitive agreement to sell its Better Health VMS business, which represents approximately 3% of the company's fiscal year 2024 net sales, and expects to incur a one-time, after-tax charge of $114 million to $134 million in the first quarter of fiscal year 2025.
• Clorox expects fiscal year 2025 net sales to be flat to down 2%, with organic sales up 3% to 5%, excluding the impact of the Argentina and VMS business divestitures.
• The company anticipates a gross margin increase of about 100 basis points in fiscal year 2025 and adjusted EPS between $6.55 and $6.80.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to strong margin expansion and adjusted EPS growth, despite a decrease in net sales and the impact of the cyberattack. The divestiture of the VMS business is a strategic move that is viewed positively, and the company's outlook for fiscal year 2025 is also positive.

Positives

• Gross margin expansion was strong in the fourth quarter and for the full year, driven by cost savings and favorable commodity costs.
• The company successfully restored distribution and regained most of the market share lost due to the cyberattack.
• Clorox completed the implementation of its streamlined operating model, which is expected to generate significant cost savings.
• The company is actively investing in its brands and digital capabilities.
• Adjusted EPS showed growth in both the fourth quarter and the full fiscal year.
• Clorox is projecting a return to volume growth in fiscal year 2025.

Negatives

• Net sales decreased by 6% in the fourth quarter and 4% for the full fiscal year.
• The company experienced lower volume and unfavorable price mix in several segments.
• The divestiture of the Argentina business negatively impacted net sales.
• The company expects to incur a significant one-time charge due to the sale of the VMS business.
• Net cash provided by operations decreased by 40% compared to the previous fiscal year.
• The Household segment experienced a 31% decrease in adjusted EBIT for the quarter.

Risks

• The company is still recovering from the cyberattack, which caused significant disruption.
• The divestiture of the VMS business will result in a one-time charge and a reduction in future sales.
• The company faces challenges from competitive activity and changing consumer preferences.
• There are risks associated with the implementation of new technologies and processes.
• The company is exposed to macroeconomic and geopolitical risks, including inflation and supply chain disruptions.
• The company is exposed to foreign currency exchange rate fluctuations.

Future Outlook

Clorox expects fiscal year 2025 net sales to be flat to down 2%, with organic sales up 3% to 5%. Gross margin is expected to increase by about 100 basis points, and adjusted EPS is projected to be between $6.55 and $6.80.

Management Comments

• We closed out the fiscal year with strong margin expansion and double-digit adjusted EPS growth despite substantial disruption and consumption loss from the cyberattack.
• While fully restoring supply and distribution, as well as recovering nearly all of our market share, we remained relentless in driving our IGNITE strategy forward.
• We made strong progress as we evolved our portfolio to accelerate profitable growth, completed the implementation of our streamlined operating model and advanced our digital transformation.
• While there is more work to do, we are confident that the actions we have taken, combined with the strength of our portfolio, position us well to deliver strong performance led by a return to volume growth in fiscal year 2025, consistent with our long-term goals.
• The Better Health VMS business will do well under the leadership of Piping Rock, as they have built a strong pure-play business in a category that is poised for growth.
• This transaction is a deliberate step in our IGNITE strategy and reflects our commitment to evolve our portfolio to drive more consistent, profitable growth.

Industry Context

The divestiture of the VMS business aligns with Clorox's strategy to focus on core brands and accelerate profitable growth. This move is consistent with trends in the consumer goods industry where companies are streamlining portfolios to improve efficiency and profitability. The company is also investing in digital transformation, which is a key trend in the industry.

Comparison to Industry Standards

• Clorox's gross margin improvement of 380 basis points in Q4 is a positive sign, indicating effective cost management, which is a key focus for consumer goods companies.
• Procter & Gamble (PG), a major competitor, also focuses on cost savings and margin expansion, but Clorox's specific initiatives, such as the streamlined operating model, are unique to the company.
• Colgate-Palmolive (CL) has also been focusing on pricing and cost management, and Clorox's performance in these areas will be closely watched by investors.
• The divestiture of the VMS business is a strategic move similar to other companies that have divested non-core assets to focus on higher-growth areas.
• Clorox's digital transformation efforts are in line with industry trends, as companies are increasingly investing in technology to improve efficiency and customer engagement.

Stakeholder Impact

• Shareholders will be impacted by the divestiture of the VMS business and the associated one-time charge, but the company's focus on core brands and profitability is expected to benefit them in the long term.
• Employees may be affected by the streamlined operating model and the divestiture of the VMS business.
• Customers will benefit from the company's continued investment in its brands and product innovation.
• Suppliers may be impacted by changes in the company's supply chain and sourcing strategies.

Next Steps

• The company will complete the sale of its Better Health VMS business in the first quarter of fiscal year 2025.
• Clorox will continue to implement its IGNITE strategy, focusing on portfolio evolution, digital transformation, and cost savings.
• The company will continue to invest in its brands and digital capabilities.
• Clorox will host a live Q&A audio webcast to discuss the results.

Key Dates

Keywords

Clorox, Financial Results, Divestiture, Vitamins, Minerals, Supplements, Gross Margin, EPS, Cyberattack, Organic Sales, Cost Savings, Streamlined Operating Model